RETRACTED: MiR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity Through PTEN and TIMP3 Downregulation

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2009 Dec 8

PMID 19962668

Citations 418

Authors

Michela Garofalo

Gianpiero Di Leva

Giulia Romano

Gerard Nuovo

Sung-Suk Suh

Apollinaire Ngankeu

Cristian Taccioli

Flavia Pichiorri

Hansjuerg Alder

Paola Secchiero

Pierluigi Gasparini

Arianna Gonelli

Stefan Costinean

Mario Acunzo

Gerolama Condorelli

Carlo Maria Croce

Affiliations

Soon will be listed here.

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the editors. This article was published on December 8, 2009. In November 2021, The Ohio State University notified the Cancer Cell editors that this article contains ten instances of plagiarized text; that Figures 1G, 5B, 5E, 7D, and 7F were falsified; and that part of Figure 1G in the article is the same as part of Figure 1B in another article that was later retracted (Garofalo et al., 2008, PLOS One 3, e4070, https://doi.org/10.1371/journal.pone.0004070). The university recommended the editors correct or retract the article. Given the extent and severity of these issues, the editors are retracting the article. S.-S. S. agrees with the retraction, and M.G., G.D.L., G.N., F.P., P.S., P.G., G.C., and C.M.C. disagree with the retraction; all other authors couldn't be reached or didn't respond.

Citing Articles

'Investigation of miRNAs That Affect the PI3K/AKT/mTOR Signaling Pathway in Endometrial Cancer'.

Oz H, Canacankatan N, Antmen S, Aytan H, Tuncel F Cell Biochem Biophys. 2025; .

PMID: 39982560 DOI: 10.1007/s12013-025-01694-6.

Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway.

Guo J, Jiang X, Lian J, Li H, Zhang F, Xie J Front Cell Dev Biol. 2024; 12:1431423.

PMID: 39156976 PMC: 11327086. DOI: 10.3389/fcell.2024.1431423.

Genetic Alchemy unveiled: MicroRNA-mediated gene therapy as the Artisan craft in the battlefront against hepatocellular carcinoma-a comprehensive chronicle of strategies and innovations.

Murshed A, Alnoud M, Ahmad S, Ullah Khan S, Alissa M, Alsuwat M Front Genet. 2024; 15:1356972.

PMID: 38915826 PMC: 11194743. DOI: 10.3389/fgene.2024.1356972.

Hypoxia‑regulated exosomal miR‑185 inhibits esophageal squamous cell carcinoma progression and predicts prognosis.

Maiyulan A, Matsumoto Y, Wang H, Murakami K, Toyozumi T, Otsuka R Oncol Lett. 2024; 28(1):334.

PMID: 38827568 PMC: 11140231. DOI: 10.3892/ol.2024.14467.

A New Approach to Melanoma Treatment: microRNAs.

Ilhan S, Oguz F, Atmaca H Curr Top Med Chem. 2024; 24(16):1362-1376.

PMID: 38676490 DOI: 10.2174/0115680266291290240417081544.

References

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

Fong Y, Liu S, Huang C, Li T, Hsu S, Kao S . Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer. 2008; 64(3):263-70. DOI: 10.1016/j.lungcan.2008.09.003. View

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R . Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004; 126(4):1005-14. DOI: 10.1053/j.gastro.2003.12.049. View

Walczak H, Miller R, Ariail K, Gliniak B, Griffith T, Kubin M . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2):157-63. DOI: 10.1038/5517. View

Cruz-Munoz W, Khokha R . The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci. 2008; 45(3):291-338. DOI: 10.1080/10408360801973244. View

Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C . MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008; 27(27):3845-55. DOI: 10.1038/onc.2008.6. View

Gabriely G, Wurdinger T, Kesari S, Esau C, Burchard J, Linsley P . MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008; 28(17):5369-80. PMC: 2519720. DOI: 10.1128/MCB.00479-08. View

Song K, Ellis E, Strom S, Chiang J . Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes. Hepatology. 2007; 46(6):1993-2002. DOI: 10.1002/hep.21878. View

Chiu R, Angel P, Karin M . Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell. 1989; 59(6):979-86. DOI: 10.1016/0092-8674(89)90754-x. View

10.

Lee J, Steelman L, Chappell W, McCubrey J . Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle. 2008; 7(5):631-6. DOI: 10.4161/cc.7.5.5416. View

11.

Ryseck R, Bravo R . c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. Oncogene. 1991; 6(4):533-42. View

12.

Kandasamy K, Srivastava R . Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 2002; 62(17):4929-37. View

13.

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

14.

Li D, Sun H . PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998; 95(26):15406-11. PMC: 28055. DOI: 10.1073/pnas.95.26.15406. View

15.

Janssen A, Hoellenriegel J, Fogarasi M, Schrewe H, Seeliger M, Tamm E . Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest Ophthalmol Vis Sci. 2008; 49(7):2812-22. DOI: 10.1167/iovs.07-1444. View

16.

Ruvkun G . Clarifications on miRNA and cancer. Science. 2006; 311(5757):36-7. DOI: 10.1126/science.311.5757.36d. View

17.

Giordano S, Di Renzo M, Narsimhan R, Cooper C, Rosa C, Comoglio P . Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene. 1989; 4(11):1383-8. View

18.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

19.

Sekido Y, Fong K, Minna J . Molecular genetics of lung cancer. Annu Rev Med. 2002; 54:73-87. DOI: 10.1146/annurev.med.54.101601.152202. View

20.

Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin G . MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008; 27(43):5651-61. DOI: 10.1038/onc.2008.178. View